Effect of cytochrome P450 polymorphism on arachidonic acid metabolism and their impact on cardiovascular diseases
about
Genetics of resistant hypertension: a novel pharmacogenomics phenotype20-HETE and blood pressure regulation: clinical implicationsSoluble epoxide hydrolase-dependent regulation of myogenic response and blood pressureAdenosine A2A receptor modulates vascular response in soluble epoxide hydrolase-null mice through CYP-epoxygenases and PPARγMetabolomic profiles delineate signature metabolic shifts during estrogen deficiency-induced bone loss in rat by GC-TOF/MSAssociation between the CYP4A11 T8590C variant and essential hypertension: new data from Han Chinese and a meta-analysisCYP2C19 variants and epoxyeicosatrienoic acids in patients with microvascular anginaGene-gene interaction between PPARG and CYP1A1 gene on coronary artery disease in the Chinese Han PopulationGenetic variation in CYP4A11 and blood pressure response to mineralocorticoid receptor antagonism or ENaC inhibition: an exploratory pilot study in African Americans.Endothelium-derived vasoactive factors and hypertension: possible roles in pathogenesis and as treatment targets.The role of 20-HETE in androgen-mediated hypertension.The association between CYP1A1 genetic polymorphisms and coronary artery disease in the Uygur and Han of ChinaCytochrome P450 2J2: distribution, function, regulation, genetic polymorphisms and clinical significance.Determination of major UDP-glucuronosyltransferase enzymes and their genotypes responsible for 20-HETE glucuronidation.Gender-Specific Effect of CYP2C8*3 on the Risk of Essential Hypertension in Bulgarian Patients.20-HETE Signals Through G-Protein-Coupled Receptor GPR75 (Gq) to Affect Vascular Function and Trigger Hypertension.Quercetin induces hepatic lipid omega-oxidation and lowers serum lipid levels in miceDiplotypes of CYP2C9 gene is associated with coronary artery disease in the Xinjiang Han population for women in China.Lipoxins as biomarkers of lupus and other inflammatory conditionsGenetic polymorphism of cytochrome P450 4F2, vitamin E level and histological response in adults and children with nonalcoholic fatty liver disease who participated in PIVENS and TONIC clinical trials.Relationship between CYP17A1 genetic polymorphism and coronary artery disease in a Chinese Han population.Ethnic Differences in the Metabolism of Toluene: Comparisons between Korean and Foreign Workers Exposed to TolueneCurrent and emerging strategies for the treatment and management of systemic lupus erythematosus based on molecular signatures of acute and chronic inflammationMolecular mechanisms regulating the vascular prostacyclin pathways and their adaptation during pregnancy and in the newborn.Relationship between CYP17A1 Genetic Polymorphism and Essential Hypertension in a Chinese PopulationUpregulation of soluble epoxide hydrolase in proximal tubular cells mediated proteinuria-induced renal damage.Soluble epoxide hydrolase inhibitor, TUPS, protects against isoprenaline-induced cardiac hypertrophy.Eicosanoids in metabolic syndrome.Genetic associations with hypertension: meta-analyses of six candidate genetic variants.Expression of CYP2A6, CYP2D6 and CYP4A11 Polymorphisms in COS7 Mammalian Cell Line.Role of cytochrome P450 epoxygenase in regulating renal membrane transport and hypertension.Sex-dependent alteration of cardiac cytochrome P450 gene expression by doxorubicin in C57Bl/6 mice.Genetic variation at the CYP2C19 gene associated with metabolic syndrome susceptibility in a South Portuguese population: results from the pilot study of the European Health Examination Survey in Portugal.20-hydroxyeicosatetraeonic acid: a new target for the treatment of hypertensionThe effect and clinical consequences of hypoxia on cytochrome P450, membrane carrier proteins activity and expression.Influence of inflammation on cardiovascular protective effects of cytochrome P450 epoxygenase-derived epoxyeicosatrienoic acids.Cytochrome P450 and ischemic heart disease: current concepts and future directions.Design and discovery of soluble epoxide hydrolase inhibitors for the treatment of cardiovascular diseases.The role of mid-chain hydroxyeicosatetraenoic acids in the pathogenesis of hypertension and cardiac hypertrophy.The role of cytochrome P450 1B1 and its associated mid-chain hydroxyeicosatetraenoic acid metabolites in the development of cardiac hypertrophy induced by isoproterenol.
P2860
Q26851506-DD745406-CC46-478D-BA21-FBE98C35D7D0Q28288942-4F292C84-D23D-473D-A36B-AD2A1D7AC937Q28384214-1719711D-0A0A-448C-913C-26A027581904Q28392991-31516F20-4286-407F-B9D7-36BB154A38C7Q28486063-D6705A45-6C88-4658-9EC1-660BB0959FE2Q30000660-5DC6DCBA-41C6-4D35-955D-52D96C936535Q33761436-2D780774-B590-47A4-890C-43F2A800EEB0Q33798385-C06A772F-2155-41F4-9283-ABAA1F2A1A3EQ33970421-66EE2046-7F16-4FBE-8AC6-7C17BC801BCCQ34023606-5BFD1E71-F5C3-4B00-99B8-598223CDC4F5Q34196923-13E86FD9-F2DF-4581-A2F6-4EED7EDFB746Q34246447-0313F9B9-3356-450E-9F67-48749203365EQ34358307-11D6096A-5D0E-48BD-97F2-197967F49DB6Q34440126-0FD5B561-8BA1-4FC8-A84B-B008F08FC10DQ34495642-8A95D4C3-53F2-486E-832A-21970C1D9FACQ34553783-6B47D49F-4497-4514-BF6A-D2BDFC0A79D9Q34566467-FB62C437-8408-4BFC-847B-C66B04C8DD3FQ34581729-D5A168BC-245C-4D03-9083-5F1275072970Q35044584-F172B896-6FDD-4125-B953-DE83615DE5E9Q35156042-20635BBC-71F8-4EE3-AA10-2155746685C1Q35176614-0FCECD0C-0A71-444A-859B-67C5A1E8F8E8Q35397407-E6A30CBB-51A7-4205-9EAD-2C1FAD39D68FQ35557372-C3E725D2-0A6D-4FDC-9B09-0F1FF0262550Q36105461-94D7D19E-CB2E-480D-852A-E64DBDB916BBQ36314874-C931CFD8-28C9-40AB-9BCC-B4AE452176C5Q36527885-35142C6E-77CD-4B8B-BAAC-9BCCF04DEEC1Q36756985-78DDBAAB-73E8-45CD-B3AF-9406597DBA39Q36911098-18F18AB7-9544-4CB8-AFE5-E3A3421B187AQ37190345-3562A583-68F5-4A9E-B8F0-F33769396F9FQ37326678-0EC645CF-D217-462F-8CA1-7FD749EA9DD1Q37483653-E871D23C-2D5F-477D-A744-969BACA02EEAQ37569491-07DD5037-569B-48CC-BBCD-13D198A572D3Q37599633-4A5BC28A-577E-474D-965F-3AD290BEB528Q37798679-C0D83EE2-F820-400E-A4CE-DEF55E9AEC88Q37880895-0310AC92-AA76-4B54-BC4C-DBDDFAAE3ABEQ38138158-0D8BA124-454B-4E35-804E-A4219AE627BAQ38166022-7534A6A2-CE28-4AC6-8274-EDEF811F0878Q38184587-D6FDC550-1EBF-4446-A2B5-CD9ECBF3D2C1Q38622658-DE547B1A-418C-43C5-A5A1-5EE236F06A53Q38714257-78AB7044-0C1F-4CFA-898B-BF2EDFCF5183
P2860
Effect of cytochrome P450 polymorphism on arachidonic acid metabolism and their impact on cardiovascular diseases
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
Effect of cytochrome P450 poly ...... act on cardiovascular diseases
@ast
Effect of cytochrome P450 poly ...... act on cardiovascular diseases
@en
Effect of cytochrome P450 poly ...... act on cardiovascular diseases
@nl
type
label
Effect of cytochrome P450 poly ...... act on cardiovascular diseases
@ast
Effect of cytochrome P450 poly ...... act on cardiovascular diseases
@en
Effect of cytochrome P450 poly ...... act on cardiovascular diseases
@nl
prefLabel
Effect of cytochrome P450 poly ...... act on cardiovascular diseases
@ast
Effect of cytochrome P450 poly ...... act on cardiovascular diseases
@en
Effect of cytochrome P450 poly ...... act on cardiovascular diseases
@nl
P1476
Effect of cytochrome P450 poly ...... act on cardiovascular diseases
@en
P2093
Ayman O S El-Kadi
P304
P356
10.1016/J.PHARMTHERA.2009.12.002
P407
P577
2010-01-20T00:00:00Z